Whether it is R&D, production or marketing capabilities, there is no doubt that Guizhou Bailing’s strong comprehensive strength as the country’s leader in Miao medicine. Not long ago, Guizhou Bailing was once again ranked among the "Top 30 Traditional Chinese Medicine Enterprises in China's Top 100 Pharmaceutical Industry List". This award is highly credible and authoritative in the industry.
In terms of research and development, Guizhou Bailing is based on traditional Chinese medicine/ethnic medicine, with original new drugs such as chemical drugs and biological drugs as two wings, aiming at four major directions: malignant tumors, metabolic diseases, infectious diseases, and clinical blank areas, and closely follows the At the forefront of international scientific research, we continue to carry out research and development of new drugs and enhance the company's product reserves and research and development capabilities. At present, the company has undertaken 7 major national science and technology special projects such as "Major New Drug Creation", more than 150 invention patents, and 17 international patents.